Objective： To evaluate the clinical efficacy of Shenqi Fuzheng injection combined with gemcitabine plus cisplatin（GP） in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： we performed a syst...Objective： To evaluate the clinical efficacy of Shenqi Fuzheng injection combined with gemcitabine plus cisplatin（GP） in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： we performed a systematicsearch in the electronic databases such as Cochrane Library, Pubmed, Embase, Chinese Journal Full-text Database,Chinese Biomedical Literature Database, Chinese Science and Technology Periodical Full-text Database andWanfang Database up to 30 January 2017. Randomized controlled trials （RCT） of Shenqi Fuzheng Injectioncombined with GP chemotherapy in the treatment of advanced NSCLC were searched, and all the RCTs wereconducted on methodological quality assessment. Data extraction and data analysis were according to standards ofCochrane systematic review. Results： Eight trials were included including a total of 701 patients. Meta-analysisresults： Shenqi Fuzheng injection combined with GP chemotherapy could significantly improve the functionalstatus of patients with NSCLC （OR = 3.44, 95% CI [2.26, 5.25], P 〈 0.0001） and clinical treatment efficacy （OR =（OR = 0.31, 95%CI [0.20, 0.47], P 〈 0.0001. The rate of leukopenia （OR = .31, 95%CI [0.20,0.47], P 〈 0.0001）,thrombocytopenia （OR = 0.58, 95%CI [0.37, 0.91], P = 0.020）, hemoglobin decline （（OR = 0.31, 95%CI [0.16,0.59], P = 0.0004） and incidence of gastrointestinal reactions （OR = 0.58,P 〈 0.05） could be reduced. Conclusion：Shenqi Fuzheng injection combined with GP chemotherapy in the treatment of advanced NSCLC obtainedsignificantly clinical efficacy. The quality of the literature incorporated is low, the conclusion requires high-qualityresearch to further prove.展开更多
Objective： In an era of ever evolving, promising new therapies for advanced non small cell lung cancer （NSCLC）, early predictors of response to therapy, are needed. We evaluated early variations in CYFRA 21-1 serum...Objective： In an era of ever evolving, promising new therapies for advanced non small cell lung cancer （NSCLC）, early predictors of response to therapy, are needed. We evaluated early variations in CYFRA 21-1 serum levels of patients with advanced NSCLC receiving first line chemotherapy and correlated the results with objective tumor response. Methods： 29 consecutive, previously untreated, patients of advanced non small cell lung cancer, with measurable disease on CT scan were evaluated. All patients were treated with conventional systemic chemotherapy, although the choice of chemotherapy was left to the discretion of the treating physicians. Serum samples were obtained immediately before the start of 1st and 2nd cycles of chemotherapy. CYFRA 21-1 was measured with an electrochemiluminescense immunoassay on an automatic analyzer （Elecsys 2000; Roche Diagnostics）. Response was evaluated using Response evaluation criteria in solid tumors （RECIST） criteria. Results： 10 patients had partial response, 9 patients had stable disease and 9 had progressive disease. None of the patients had complete response. 21/29 （72%） patients had an elevated baseline value of CYFRA 21-1.62% patients （18/29） had a decrease in CYFRA 21-1 after 1 cycle of chemotherapy. The average reduction in the 2nd reading was irrespective of whether baseline value was normal or not. The average reduction was statistically significant （P = 0.002; 95% CI, from 0.8369 to 3.49464; t test）. 8 out of 10 （80%） patients with partial response had a reduction in their 2nd reading of. CYFRA （P = 0.019; 95% CI, from 0.81965 to 7.20035; t test） which was significant. We also observed that 6/9 （66%） patients whose disease remains stable also had a decrease in their subsequent reading （P = 0.0106; 95% CI, from -0.44942 to 3.82720; t test）, though it was not significant statistically. Although 5 out of 9 （55%） patients, who had an increase in their CYFRA 21-1 level, had progressive disease, but it was not statistically significant （P = 0.537; 95% CI, from -1.20021 to 2.13354; ttest）. 14 out of 19 （73%） who either had partial response or had stable disease, had a reduction in their 2nd value of CYFRA 21-1 and was significant statistically （P = 0.004; 95% CI, from 0.74792 to 3.50208; t test）. We also observed that except for 1 patient, all patients who had a decrease of 42% or more in their subsequent CYFRA 21-1 level, were those who had either responded to chemotherapy or had stable disease （P = 0.001）, which was statistically significant. Conclusion： We can conclude that monitoring of serum marker CYFRA 21-1, early dudng first-line chemotherapy may be a useful prognostic tool for evaluation of early tumor response in patients with advanced NSCLC.展开更多
Increasing evidence indicates that aberrant expressions of some microRNAs are associated with cancer progression.However,the roles and biological mechanisms of miRNA-16-5p in human non-small cell lung cancer(NSCLC)are...Increasing evidence indicates that aberrant expressions of some microRNAs are associated with cancer progression.However,the roles and biological mechanisms of miRNA-16-5p in human non-small cell lung cancer(NSCLC)are not to be well studied.Here,we validated that the expression of miR-16-5p was decreased significantly in NSCLC samples and cell lines.The correlation between the clinicopathological features of NSCLC and the miR-16-5p expression showed that the expression of miR-16-5p in non-small cell lung cancer was linked with the advanced TNM stage,positive lymph node metastasis,with short overall survival(OS).Also,a negative correlation between miR-16-5p and Fermitin family member 2(FERMT2)was observed,implying there may be a potential link about their regulation.The hypothesis was further confirmed by in-silico analysis and dual-luciferase reporter assay.Moreover,we demonstrated that the transfections of miR-16-5p mimics could alter some biological characteristics of NSCLC cells remarkably accomplished by the expression variance of FERMT2 in vitro and in vivo assays.Summarily,this study demonstrated that miR-16-5p,as a tumor suppression factor in NSCLC by targeting FERMT2,could serve as one promising biomarker in the prediction for NSCLC patients.展开更多
The rational for the study was to assess the levels of endocrine disrupting trace metals in River Samre. The levels of Mercury ranged from 0.01 to 0.02 mg/l (mean of 0.006 mg/l), whiles cadmium levels ranged from 0.00...The rational for the study was to assess the levels of endocrine disrupting trace metals in River Samre. The levels of Mercury ranged from 0.01 to 0.02 mg/l (mean of 0.006 mg/l), whiles cadmium levels ranged from 0.002 to 0.011 mg/l (mean of 0.01 mg/l). The high levels of Hg and Cd may have adverse effects on the endocrine system of inhabitants who drink directly from the river without treatment. High levels of mercury and cadmium might be caused by the activities of a Timber and Plywood Company located close to the river and the underlying bedrocks of the area exposed as a result of human activities such as farming. The concentration of lead was below detection limit ( mg/l) but that of Arsenic ranged from 0.001 to 0.007 mg/l (mean of 0.005). Health risk assessment conducted shows that the risk associated with exposure to these metals for now are low. Continuous water quality monitoring is recommended to help protect the resource and also to safeguard human health.展开更多
Paraneoplastic syndromes are signs or symptoms that occur as a result of organ or tissue damage at locations remote from the site of the primary tumor or metastases. Paraneoplastic syndromes associated with lung cance...Paraneoplastic syndromes are signs or symptoms that occur as a result of organ or tissue damage at locations remote from the site of the primary tumor or metastases. Paraneoplastic syndromes associated with lung cancer can impair various organ functions and include neurologic, endocrine, dermatologic, rheumatologic, hematologic, and ophthalmological syndromes, as well as glomerulopathy and coagulopathy(Trousseau's syndrome). The histological type of lung cancer is generally dependent on the associated syndrome, the two most common of which are humoral hypercalcemia of malignancy in squamous cell carcinoma and the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. The symptoms often precede the diagnosis of the associated lung cancer, especially when the symptoms are neurologic or dermatologic. The proposed mechanisms of paraneoplastic processes include the aberrant release of humoral mediators, such as hormones and hormone-like peptides, cyto-kines, and antibodies. Treating the underlying cancer is generally the most effective therapy for paraneoplastic syndromes, and treatment soon after symptom onset appears to offer the best potential for symptom improvement. In this article, we review the diagnosis, potential mechanisms, and treatments of a wide variety of paraneoplastic syndromes associated with lung cancer.展开更多
Objective 14-3-3-zeta protein has been found to be associated with survival signaling in cancer.However,prognostic value and the predictive effect of its gene expression for determining the efficacy of endocrine thera...Objective 14-3-3-zeta protein has been found to be associated with survival signaling in cancer.However,prognostic value and the predictive effect of its gene expression for determining the efficacy of endocrine therapy in breast cancer are unclear.Methods The differential 14-3-3-zeta gene expression between cancer and normal tissue was assayed using ONCOMINE database analysis.The correlation between 14-3-3-zeta gene and proliferative/metastasis-associated genes was analyzed using Breast Cancer Gene-Expression Miner v4.1(bc-Gen Ex Miner v4.1).The prognostic value of its expression in breast cancer was analyzed using bc-Gen Ex Miner v4.1 and Kaplan-Meier Plotter.Results The 14-3-3-zeta gene expression was elevated in breast cancer tissue compared with normal breast tissue,which was higher in invasive ductal breast cancer than in ductal breast cancer in situ.It was also positively correlated with the degree of malignancy and the clinical stage of breast cancer and with some proliferative genes.A high level of 14-3-3-zeta expression was predictive of shorter relapse-free survival(RFS)in ER-positive but not ER-negative breast cancer.Further analysis showed the association of high 14-3-3-zeta expression and a shorter RFS in endocrine therapy or tamoxifen-only-treated population,regardless of whether chemotherapy had been used.Conclusion 14-3-3-zeta gene expression is upregulated and associated with a relatively high degree of malignancy and late clinical stage in breast cancer.It is a promising prognostic factor for ER-positive breast cancer and a predictor of the efficacy of endocrine therapy.展开更多
Background:Non–small cell lung cancer(NSCLC)is a common malignant tumor with an increasing incidence.PIEZO-type mechanosensitive ion channel component 1(PIEZO1)is a mechanosensitive ion channel whose expression has b...Background:Non–small cell lung cancer(NSCLC)is a common malignant tumor with an increasing incidence.PIEZO-type mechanosensitive ion channel component 1(PIEZO1)is a mechanosensitive ion channel whose expression has been implicated in various cancers.However,its expression patterns,prognostic implications,and specific molecular mechanisms of action in NSCLC remain un-clear.This study aimed to characterize the expression profile of PIEZO1 in NSCLC in vitro and using bioinformatics analyses.Methods:To determine the expression profile of PIEZO1 in normal and cancerous human tissues and the mRNA expression of PIEZO1 in NSCLC,we analyzed data from The Cancer Genome Atlas.Various bioinformatics analyses were performed for correlation analyses,construction of survival curves,and identification of upstream mRNA targets and genes coexpressed with PIEZO1.Furthermore,the coexpressed genes were functionally annotated with Gene Ontology and subjected to pathway enrichment analyses.Additionally,we an-alyzed and compared PIEZO1 expression in normal and cancerous human tissue samples in vitro.Results:NSCLC tissue samples had lower PIEZO1 expression than adjacent tissues.PIEZO1 overexpression inhibited NSCLC progres-sion and cell migration and correlated with improved survival outcomes,as revealed by bioinformatics analyses.Additionally,analysis using the OncomiR database revealed that miR-942-5p upregulation contributed to the downregulation of PIEZO1 in NSCLC.Mechanistic in-vestigations suggested that PIEZO1 modulates NSCLC by regulating the mitogen-activated protein kinase pathway,particularly by targeting FLNA,RRAS,and MAP3K6.Bioinformatics analyses highlighted the potential of PIEZO1 as a therapeutic target and prognostic indicator of NSCLC.Conclusions:These novel findings reveal the expression profile of PIEZO1 in NSCLC and highlight the potential of PIEZO1 and miR-942-5p as diagnostic and therapeutic biomarkers of NSCLC and other cancer types.展开更多
文摘Objective： To evaluate the clinical efficacy of Shenqi Fuzheng injection combined with gemcitabine plus cisplatin（GP） in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： we performed a systematicsearch in the electronic databases such as Cochrane Library, Pubmed, Embase, Chinese Journal Full-text Database,Chinese Biomedical Literature Database, Chinese Science and Technology Periodical Full-text Database andWanfang Database up to 30 January 2017. Randomized controlled trials （RCT） of Shenqi Fuzheng Injectioncombined with GP chemotherapy in the treatment of advanced NSCLC were searched, and all the RCTs wereconducted on methodological quality assessment. Data extraction and data analysis were according to standards ofCochrane systematic review. Results： Eight trials were included including a total of 701 patients. Meta-analysisresults： Shenqi Fuzheng injection combined with GP chemotherapy could significantly improve the functionalstatus of patients with NSCLC （OR = 3.44, 95% CI [2.26, 5.25], P 〈 0.0001） and clinical treatment efficacy （OR =（OR = 0.31, 95%CI [0.20, 0.47], P 〈 0.0001. The rate of leukopenia （OR = .31, 95%CI [0.20,0.47], P 〈 0.0001）,thrombocytopenia （OR = 0.58, 95%CI [0.37, 0.91], P = 0.020）, hemoglobin decline （（OR = 0.31, 95%CI [0.16,0.59], P = 0.0004） and incidence of gastrointestinal reactions （OR = 0.58,P 〈 0.05） could be reduced. Conclusion：Shenqi Fuzheng injection combined with GP chemotherapy in the treatment of advanced NSCLC obtainedsignificantly clinical efficacy. The quality of the literature incorporated is low, the conclusion requires high-qualityresearch to further prove.
文摘Objective： In an era of ever evolving, promising new therapies for advanced non small cell lung cancer （NSCLC）, early predictors of response to therapy, are needed. We evaluated early variations in CYFRA 21-1 serum levels of patients with advanced NSCLC receiving first line chemotherapy and correlated the results with objective tumor response. Methods： 29 consecutive, previously untreated, patients of advanced non small cell lung cancer, with measurable disease on CT scan were evaluated. All patients were treated with conventional systemic chemotherapy, although the choice of chemotherapy was left to the discretion of the treating physicians. Serum samples were obtained immediately before the start of 1st and 2nd cycles of chemotherapy. CYFRA 21-1 was measured with an electrochemiluminescense immunoassay on an automatic analyzer （Elecsys 2000; Roche Diagnostics）. Response was evaluated using Response evaluation criteria in solid tumors （RECIST） criteria. Results： 10 patients had partial response, 9 patients had stable disease and 9 had progressive disease. None of the patients had complete response. 21/29 （72%） patients had an elevated baseline value of CYFRA 21-1.62% patients （18/29） had a decrease in CYFRA 21-1 after 1 cycle of chemotherapy. The average reduction in the 2nd reading was irrespective of whether baseline value was normal or not. The average reduction was statistically significant （P = 0.002; 95% CI, from 0.8369 to 3.49464; t test）. 8 out of 10 （80%） patients with partial response had a reduction in their 2nd reading of. CYFRA （P = 0.019; 95% CI, from 0.81965 to 7.20035; t test） which was significant. We also observed that 6/9 （66%） patients whose disease remains stable also had a decrease in their subsequent reading （P = 0.0106; 95% CI, from -0.44942 to 3.82720; t test）, though it was not significant statistically. Although 5 out of 9 （55%） patients, who had an increase in their CYFRA 21-1 level, had progressive disease, but it was not statistically significant （P = 0.537; 95% CI, from -1.20021 to 2.13354; ttest）. 14 out of 19 （73%） who either had partial response or had stable disease, had a reduction in their 2nd value of CYFRA 21-1 and was significant statistically （P = 0.004; 95% CI, from 0.74792 to 3.50208; t test）. We also observed that except for 1 patient, all patients who had a decrease of 42% or more in their subsequent CYFRA 21-1 level, were those who had either responded to chemotherapy or had stable disease （P = 0.001）, which was statistically significant. Conclusion： We can conclude that monitoring of serum marker CYFRA 21-1, early dudng first-line chemotherapy may be a useful prognostic tool for evaluation of early tumor response in patients with advanced NSCLC.
基金was supported by grants from the National Natural Science Foundation of China(No.81772281)the Shandong Province Taishan Scholar Project(No.ts201712067)+1 种基金the Major Research and Development Program of Shandong Province(No.2017GSF18124)the Natural Science Foundation of Shandong Province(No.ZR2020MH218).
文摘Increasing evidence indicates that aberrant expressions of some microRNAs are associated with cancer progression.However,the roles and biological mechanisms of miRNA-16-5p in human non-small cell lung cancer(NSCLC)are not to be well studied.Here,we validated that the expression of miR-16-5p was decreased significantly in NSCLC samples and cell lines.The correlation between the clinicopathological features of NSCLC and the miR-16-5p expression showed that the expression of miR-16-5p in non-small cell lung cancer was linked with the advanced TNM stage,positive lymph node metastasis,with short overall survival(OS).Also,a negative correlation between miR-16-5p and Fermitin family member 2(FERMT2)was observed,implying there may be a potential link about their regulation.The hypothesis was further confirmed by in-silico analysis and dual-luciferase reporter assay.Moreover,we demonstrated that the transfections of miR-16-5p mimics could alter some biological characteristics of NSCLC cells remarkably accomplished by the expression variance of FERMT2 in vitro and in vivo assays.Summarily,this study demonstrated that miR-16-5p,as a tumor suppression factor in NSCLC by targeting FERMT2,could serve as one promising biomarker in the prediction for NSCLC patients.
文摘The rational for the study was to assess the levels of endocrine disrupting trace metals in River Samre. The levels of Mercury ranged from 0.01 to 0.02 mg/l (mean of 0.006 mg/l), whiles cadmium levels ranged from 0.002 to 0.011 mg/l (mean of 0.01 mg/l). The high levels of Hg and Cd may have adverse effects on the endocrine system of inhabitants who drink directly from the river without treatment. High levels of mercury and cadmium might be caused by the activities of a Timber and Plywood Company located close to the river and the underlying bedrocks of the area exposed as a result of human activities such as farming. The concentration of lead was below detection limit ( mg/l) but that of Arsenic ranged from 0.001 to 0.007 mg/l (mean of 0.005). Health risk assessment conducted shows that the risk associated with exposure to these metals for now are low. Continuous water quality monitoring is recommended to help protect the resource and also to safeguard human health.
文摘Paraneoplastic syndromes are signs or symptoms that occur as a result of organ or tissue damage at locations remote from the site of the primary tumor or metastases. Paraneoplastic syndromes associated with lung cancer can impair various organ functions and include neurologic, endocrine, dermatologic, rheumatologic, hematologic, and ophthalmological syndromes, as well as glomerulopathy and coagulopathy(Trousseau's syndrome). The histological type of lung cancer is generally dependent on the associated syndrome, the two most common of which are humoral hypercalcemia of malignancy in squamous cell carcinoma and the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. The symptoms often precede the diagnosis of the associated lung cancer, especially when the symptoms are neurologic or dermatologic. The proposed mechanisms of paraneoplastic processes include the aberrant release of humoral mediators, such as hormones and hormone-like peptides, cyto-kines, and antibodies. Treating the underlying cancer is generally the most effective therapy for paraneoplastic syndromes, and treatment soon after symptom onset appears to offer the best potential for symptom improvement. In this article, we review the diagnosis, potential mechanisms, and treatments of a wide variety of paraneoplastic syndromes associated with lung cancer.
基金Science and Technology Foundation of Liaoning Provincegrant number:20170540995+5 种基金Science and Technology Foundation of Shenyang Citygrant number:RC170545the National Science Foundation of Chinagrant number:81302313Talent Project of Shengjing Hospital of China Medical Universitygrant number:345
文摘Objective 14-3-3-zeta protein has been found to be associated with survival signaling in cancer.However,prognostic value and the predictive effect of its gene expression for determining the efficacy of endocrine therapy in breast cancer are unclear.Methods The differential 14-3-3-zeta gene expression between cancer and normal tissue was assayed using ONCOMINE database analysis.The correlation between 14-3-3-zeta gene and proliferative/metastasis-associated genes was analyzed using Breast Cancer Gene-Expression Miner v4.1(bc-Gen Ex Miner v4.1).The prognostic value of its expression in breast cancer was analyzed using bc-Gen Ex Miner v4.1 and Kaplan-Meier Plotter.Results The 14-3-3-zeta gene expression was elevated in breast cancer tissue compared with normal breast tissue,which was higher in invasive ductal breast cancer than in ductal breast cancer in situ.It was also positively correlated with the degree of malignancy and the clinical stage of breast cancer and with some proliferative genes.A high level of 14-3-3-zeta expression was predictive of shorter relapse-free survival(RFS)in ER-positive but not ER-negative breast cancer.Further analysis showed the association of high 14-3-3-zeta expression and a shorter RFS in endocrine therapy or tamoxifen-only-treated population,regardless of whether chemotherapy had been used.Conclusion 14-3-3-zeta gene expression is upregulated and associated with a relatively high degree of malignancy and late clinical stage in breast cancer.It is a promising prognostic factor for ER-positive breast cancer and a predictor of the efficacy of endocrine therapy.
基金supported by grants from the Hefei Municipal Health Commission Applied Medical Research Project(no.Hwk2021yb012)Hefei Municipal Health Commission Applied Medical Research Project(no.Hwk2023zd007).
文摘Background:Non–small cell lung cancer(NSCLC)is a common malignant tumor with an increasing incidence.PIEZO-type mechanosensitive ion channel component 1(PIEZO1)is a mechanosensitive ion channel whose expression has been implicated in various cancers.However,its expression patterns,prognostic implications,and specific molecular mechanisms of action in NSCLC remain un-clear.This study aimed to characterize the expression profile of PIEZO1 in NSCLC in vitro and using bioinformatics analyses.Methods:To determine the expression profile of PIEZO1 in normal and cancerous human tissues and the mRNA expression of PIEZO1 in NSCLC,we analyzed data from The Cancer Genome Atlas.Various bioinformatics analyses were performed for correlation analyses,construction of survival curves,and identification of upstream mRNA targets and genes coexpressed with PIEZO1.Furthermore,the coexpressed genes were functionally annotated with Gene Ontology and subjected to pathway enrichment analyses.Additionally,we an-alyzed and compared PIEZO1 expression in normal and cancerous human tissue samples in vitro.Results:NSCLC tissue samples had lower PIEZO1 expression than adjacent tissues.PIEZO1 overexpression inhibited NSCLC progres-sion and cell migration and correlated with improved survival outcomes,as revealed by bioinformatics analyses.Additionally,analysis using the OncomiR database revealed that miR-942-5p upregulation contributed to the downregulation of PIEZO1 in NSCLC.Mechanistic in-vestigations suggested that PIEZO1 modulates NSCLC by regulating the mitogen-activated protein kinase pathway,particularly by targeting FLNA,RRAS,and MAP3K6.Bioinformatics analyses highlighted the potential of PIEZO1 as a therapeutic target and prognostic indicator of NSCLC.Conclusions:These novel findings reveal the expression profile of PIEZO1 in NSCLC and highlight the potential of PIEZO1 and miR-942-5p as diagnostic and therapeutic biomarkers of NSCLC and other cancer types.
